BioSpace News Archive

EV Biologics Corp., OTC PINK:YECO, is taking this opportunity to update our shareholders and other investors concerning the status of our name change submission to the Financial Industry Regulatory Authority (FINRA). As some might be aware, such submissions can be a lengthy and complex process, requiring notarized documents.

Artiva Biotherapeutics appoints Elizabeth L. Hougen, EVP and CFO of Ionis Pharmaceuticals, Inc., has extensive experience in finance and business for public life sciences companies Linda M. Kozick, who led the immuno-oncology product and portfolio strategy for BMS, including Opdivo ® and Yervoy ® , has deep expertise in strategic commercial drug development

Latest Funding Fuels World’s Most Advanced BCI Company to Continue Expanding its Platform for Life Changing Applications and Driving Clinical Studies

Teneobio, Inc., a clinical stage biotech company focused on the discovery and development of novel multi-specific biotherapeutic antibodies, announced today the publication of its bispecific human heavy chain only antibody (TNB-409) with selective IL-2βγ receptor heterodimeric agonist activity in Scientific Reports ( www.nature.com/articles/s41598-021-90096-8 ).

Metacrine, Inc. (NASDAQ:MTCR), a clinical-stage biopharmaceutical company pioneering differentiated therapies for patients with liver and gastrointestinal diseases, today announced that it will present new preclinical data demonstrating the synergistic effect of MET642, a farnesoid X receptor (FXR) agonist, when combined with tofacitinib, a JAK inhibitor, in improving inflammatory bowel disease (IBD) at Digestive Disease Week (DDW) 2021.

Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, today announced that the management team from Fortress’ commercial dermatology partner company, Journey Medical Corporation, will be featured in a webinar hosted by Scott R. Henry,

Tevard Biosciences, a privately-held biotechnology company pioneering tRNA-based gene therapies for rare and severe genetic diseases, today announced the appointment of Gopi Shanker , Ph.D., as Chief Scientific Officer and as a member of the company’s executive leadership team.

Vireo Health International, Inc. (“Vireo” or the “Company”) (CSE: VREO; OTCQX: VREOF), the leading physician-led, science-focused multi-state cannabis company, today announced that it will host a series of online virtual events for the institutional and retail investment communities on Tuesday, June 8, 2021 and Wednesday, June 9, 2021 .

InterVenn Biosciences today announced Regina Benjamin, MD, MBA, has joined the Company’s Board of Advisors, effective March 25, 2021. Dr. Benjamin joins the InterVenn Board of Advisors with extensive experience in prevention and population health.

Despite significant disruption and reprioritization of clinical trial activity during 2020 due to COVID-19, R&D activity levels remained at historically high levels, driven by new funding and strategic transactions, especially within oncology, according to a new research report Global Trends in R&D: Overview Through 2020 released by the IQVIA™ Institute for Human Data Science.